Stifel Nicolaus Has Lowered Expectations for Zoetis (NYSE:ZTS) Stock Price

Zoetis (NYSE:ZTS) had its price target reduced by equities research analysts at Stifel Nicolaus from $85.00 to $80.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has a “hold” rating on the stock. Stifel Nicolaus’ target price indicates a potential upside of 4.19% from the stock’s current price.

A number of other analysts also recently weighed in on the company. Weiss Ratings downgraded Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, June 12th. HSBC cut their price objective on Zoetis from $140.00 to $95.00 and set a “buy” rating for the company in a research report on Monday, July 6th. BNP Paribas Exane decreased their target price on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 11th. William Blair reaffirmed a “market perform” rating on shares of Zoetis in a research note on Thursday, August 6th. Finally, Barclays cut their price target on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a report on Wednesday, July 1st. Eight investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $109.23.

Zoetis Trading Up 3.8%

Shares of ZTS stock opened at $76.78 on Thursday. The business’s 50 day moving average is $75.92 and its two-hundred day moving average is $97.81. Zoetis has a twelve month low of $71.00 and a twelve month high of $160.48. The company has a market capitalization of $31.73 billion, a P/E ratio of 12.65, a price-to-earnings-growth ratio of 1.73 and a beta of 0.74. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.85 by $0.02. The business had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The company’s revenue for the quarter was down .2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Equities analysts forecast that Zoetis will post 6.2 EPS for the current year.

Institutional Trading of Zoetis

A number of institutional investors have recently bought and sold shares of ZTS. University of Texas Texas AM Investment Management Co. purchased a new position in Zoetis during the 2nd quarter valued at about $25,000. Dunhill Financial LLC lifted its holdings in shares of Zoetis by 519.3% in the second quarter. Dunhill Financial LLC now owns 353 shares of the company’s stock valued at $25,000 after purchasing an additional 296 shares in the last quarter. Prosperity Bancshares Inc acquired a new stake in shares of Zoetis in the fourth quarter valued at approximately $25,000. Cassaday & Co Wealth Management LLC acquired a new stake in shares of Zoetis in the first quarter valued at approximately $28,000. Finally, Root Financial Partners LLC increased its stake in shares of Zoetis by 66.5% during the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after purchasing an additional 103 shares in the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.